SDC1 and inflammatory breast carcinoma: For instance, signaling via the IL-6/STAT-3, Notch and EGFR signaling axis through the cell surface receptor syndecan-1 (CD138) has been established as a novel regulatory pathway responsible for the CSC phenotype in inflammatory breast cancer [60].